# Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome

> **NCT02957123** · PHASE1,PHASE2 · COMPLETED · sponsor: **Russian Academy of Medical Sciences** · enrollment: 30 (actual)

## Conditions studied

- Organic Brain Syndrome, Nonpsychotic
- Neurocognitive Disorders
- Mental Disorder, Organic
- Delirium, Dementia, Amnestic, Cognitive Disorders
- Nonpsychotic Organic Brain Syndrome
- Organic Mental Disorder
- Encephalopathy, Post-Traumatic, Chronic
- Encephalopathy, Ischemic
- Brain Ischemia

## Interventions

- **DRUG:** Intranasal auto-M2-BFs

## Key facts

- **NCT ID:** NCT02957123
- **Lead sponsor:** Russian Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2020-09
- **Final completion:** 2020-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02957123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02957123, "Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02957123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*